Comparative analysis of transcriptome remodeling in plaque-associated and plaque-distant microglia during amyloid-β pathology progression in mice.


Journal

Journal of neuroinflammation
ISSN: 1742-2094
Titre abrégé: J Neuroinflammation
Pays: England
ID NLM: 101222974

Informations de publication

Date de publication:
24 Sep 2022
Historique:
received: 09 12 2021
accepted: 24 08 2022
entrez: 24 9 2022
pubmed: 25 9 2022
medline: 28 9 2022
Statut: epublish

Résumé

Research in recent years firmly established that microglial cells play an important role in the pathogenesis of Alzheimer's disease (AD). In parallel, a series of studies showed that, under both homeostatic and pathological conditions, microglia are a heterogeneous cell population. In AD, amyloid-β (Aβ) plaque-associated microglia (PAM) display a clearly distinct phenotype compared to plaque-distant microglia (PCM), suggesting that these two microglia subtypes likely differently contribute to disease progression. So far, molecular characterization of PAM was performed indirectly using single cell RNA sequencing (scRNA-seq) approaches or based on markers that are supposedly up-regulated in this microglia subpopulation. In this study based on a well-characterized AD mouse model, we combined cell-specific laser capture microdissection and RNA-seq analysis to i) identify, without preconceived notions of the molecular and/or functional changes that would affect these cells, the genes and gene networks that are dysregulated in PAM or PCM at three critical stages of the disease, and ii) to investigate the potential contribution of both plaque-associated and plaque-distant microglia. First, we established that our approach allows selective isolation of microglia, while preserving spatial information and preventing transcriptome changes induced by classical purification approaches. Then, we identified, in PAM and PCM subpopulations, networks of co-deregulated genes and analyzed their potential functional roles in AD. Finally, we investigated the dynamics of microglia transcriptomic remodeling at early, intermediate and late stages of the disease and validated select findings in postmortem human AD brain. Our comprehensive study provides useful transcriptomic information regarding the respective contribution of PAM and PCM across the Aβ pathology progression. It highlights specific pathways that would require further study to decipher their roles across disease progression. It demonstrates that the proximity of microglia to Aβ-plaques dramatically alters the microglial transcriptome and reveals that these changes can have both positive and negative impacts on the surrounding cells. These opposing effects may be driven by local microglia heterogeneity also demonstrated by this study. Our approach leads to molecularly define the less well studied plaque-distant microglia. We show that plaque-distant microglia are not bystanders of the disease, although the transcriptomic changes are far less striking compared to what is observed in plaque-associated microglia. In particular, our results suggest they may be involved in Aβ oligomer detection and in Aβ-plaque initiation, with increased contribution as the disease progresses.

Sections du résumé

BACKGROUND BACKGROUND
Research in recent years firmly established that microglial cells play an important role in the pathogenesis of Alzheimer's disease (AD). In parallel, a series of studies showed that, under both homeostatic and pathological conditions, microglia are a heterogeneous cell population. In AD, amyloid-β (Aβ) plaque-associated microglia (PAM) display a clearly distinct phenotype compared to plaque-distant microglia (PCM), suggesting that these two microglia subtypes likely differently contribute to disease progression. So far, molecular characterization of PAM was performed indirectly using single cell RNA sequencing (scRNA-seq) approaches or based on markers that are supposedly up-regulated in this microglia subpopulation.
METHODS METHODS
In this study based on a well-characterized AD mouse model, we combined cell-specific laser capture microdissection and RNA-seq analysis to i) identify, without preconceived notions of the molecular and/or functional changes that would affect these cells, the genes and gene networks that are dysregulated in PAM or PCM at three critical stages of the disease, and ii) to investigate the potential contribution of both plaque-associated and plaque-distant microglia.
RESULTS RESULTS
First, we established that our approach allows selective isolation of microglia, while preserving spatial information and preventing transcriptome changes induced by classical purification approaches. Then, we identified, in PAM and PCM subpopulations, networks of co-deregulated genes and analyzed their potential functional roles in AD. Finally, we investigated the dynamics of microglia transcriptomic remodeling at early, intermediate and late stages of the disease and validated select findings in postmortem human AD brain.
CONCLUSIONS CONCLUSIONS
Our comprehensive study provides useful transcriptomic information regarding the respective contribution of PAM and PCM across the Aβ pathology progression. It highlights specific pathways that would require further study to decipher their roles across disease progression. It demonstrates that the proximity of microglia to Aβ-plaques dramatically alters the microglial transcriptome and reveals that these changes can have both positive and negative impacts on the surrounding cells. These opposing effects may be driven by local microglia heterogeneity also demonstrated by this study. Our approach leads to molecularly define the less well studied plaque-distant microglia. We show that plaque-distant microglia are not bystanders of the disease, although the transcriptomic changes are far less striking compared to what is observed in plaque-associated microglia. In particular, our results suggest they may be involved in Aβ oligomer detection and in Aβ-plaque initiation, with increased contribution as the disease progresses.

Identifiants

pubmed: 36153535
doi: 10.1186/s12974-022-02581-0
pii: 10.1186/s12974-022-02581-0
pmc: PMC9508749
doi:

Substances chimiques

Amyloid beta-Peptides 0
Amyloid beta-Protein Precursor 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

234

Subventions

Organisme : Labex ICST
ID : ANR 11-LABX-0015
Organisme : NIA NIH HHS
ID : R56 AG072599
Pays : United States
Organisme : NIA NIH HHS
ID : P01 AG014449
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG074004
Pays : United States
Organisme : NIA NIH HHS
ID : P01 AG017617
Pays : United States

Informations de copyright

© 2022. The Author(s).

Références

J Immunol. 2012 Jan 1;188(1):29-36
pubmed: 22079990
Cell. 2017 Jun 15;169(7):1276-1290.e17
pubmed: 28602351
Acta Neuropathol. 2008 Nov;116(5):507-15
pubmed: 18810470
Cell. 2015 Mar 12;160(6):1061-71
pubmed: 25728668
Immunity. 2017 Sep 19;47(3):566-581.e9
pubmed: 28930663
Front Aging Neurosci. 2018 May 11;10:140
pubmed: 29867449
Nat Neurosci. 2013 Dec;16(12):1896-905
pubmed: 24162652
J Cell Biol. 2018 Feb 5;217(2):459-472
pubmed: 29196460
Mol Neurodegener. 2021 Mar 22;16(1):18
pubmed: 33752701
J Neurosci. 2017 Jan 4;37(1):152-163
pubmed: 28053038
Nucleic Acids Res. 1999 Jan 1;27(1):29-34
pubmed: 9847135
Neurobiol Aging. 2014 Dec;35(12):2746-2760
pubmed: 25002035
EMBO Mol Med. 2020 Mar 6;12(3):e10606
pubmed: 31951107
Neuroscience. 2016 Aug 25;330:410-20
pubmed: 27288150
Brain Res. 2021 Sep 15;1767:147569
pubmed: 34197775
Prog Neuropsychopharmacol Biol Psychiatry. 2017 Oct 3;79(Pt A):15-18
pubmed: 28189704
Brain Behav Immun. 2021 Jan;91:404-417
pubmed: 33190798
Bioinformatics. 2014 Apr 1;30(7):923-30
pubmed: 24227677
Cell Rep. 2019 Feb 26;26(9):2477-2493.e9
pubmed: 30811995
Immunity. 2019 Jan 15;50(1):253-271.e6
pubmed: 30471926
Annu Rev Physiol. 2017 Feb 10;79:619-643
pubmed: 27959620
Cell Rep. 2019 Apr 23;27(4):1293-1306.e6
pubmed: 31018141
Ann Neurol. 2017 Aug;82(2):311-314
pubmed: 28727176
Transl Psychiatry. 2018 May 18;8(1):99
pubmed: 29777097
Hippocampus. 2019 May;29(5):422-439
pubmed: 28888073
J Neurosci. 2006 Sep 27;26(39):9956-66
pubmed: 17005859
Nat Protoc. 2012 Mar 01;7(3):562-78
pubmed: 22383036
Glia. 2018 May;66(5):971-986
pubmed: 29399880
Cell. 2020 Aug 20;182(4):976-991.e19
pubmed: 32702314
Science. 2002 Jul 19;297(5580):353-6
pubmed: 12130773
J Exp Med. 2020 Apr 6;217(4):
pubmed: 31967645
Neurobiol Aging. 2017 Oct;58:41-53
pubmed: 28697378
Front Immunol. 2019 Jul 04;10:1473
pubmed: 31333644
Acta Neuropathol Commun. 2022 Jun 22;10(1):91
pubmed: 35733193
Biomol Eng. 2001 Jun;17(6):157-65
pubmed: 11337275
Nat Protoc. 2019 Feb;14(2):482-517
pubmed: 30664679
Nat Commun. 2021 May 21;12(1):3015
pubmed: 34021136
Nat Immunol. 2021 May;22(5):586-594
pubmed: 33859405
J Neuroinflammation. 2018 Sep 6;15(1):256
pubmed: 30189875
Nucleic Acids Res. 2020 Jan 8;48(D1):D498-D503
pubmed: 31691815
Sci Rep. 2020 Jul 22;10(1):12210
pubmed: 32699331
Neurobiol Aging. 2017 Jul;55:115-122
pubmed: 28434692
Nat Rev Immunol. 2015 Apr;15(4):203-16
pubmed: 25720354
Nat Immunol. 2018 Jun;19(6):636-644
pubmed: 29777220
J Neurosci Methods. 2021 Feb 15;350:109038
pubmed: 33338543
Stat Appl Genet Mol Biol. 2005;4:Article17
pubmed: 16646834
J Neurosci. 2018 Feb 7;38(6):1335-1350
pubmed: 29295823
Nat Rev Mol Cell Biol. 2001 Feb;2(2):107-17
pubmed: 11252952
Cell Rep. 2020 Jun 30;31(13):107843
pubmed: 32610143
Neurobiol Aging. 2004 Aug;25(7):885-92
pubmed: 15212842
Cell Rep. 2017 Oct 10;21(2):366-380
pubmed: 29020624
Acta Neuropathol Commun. 2021 Jan 5;9(1):1
pubmed: 33402227
Brain. 2018 Jun 1;141(6):1855-1870
pubmed: 29608645
EMBO Rep. 2018 Nov;19(11):
pubmed: 30206190
Brain. 2017 Mar 1;140(3):792-803
pubmed: 28122877
Mol Neurobiol. 2021 Oct;58(10):5141-5162
pubmed: 34263425
Biol Psychiatry. 2018 Feb 15;83(4):377-387
pubmed: 29169609
Handb Clin Neurol. 2017;145:325-337
pubmed: 28987180
J Alzheimers Dis. 2021;79(3):961-968
pubmed: 33361603
Acta Neuropathol. 2021 May;141(5):681-696
pubmed: 33609158
Mol Neurodegener. 2017 Jun 12;12(1):47
pubmed: 28606182
Glia. 2018 Jul;66(7):1464-1480
pubmed: 29493017
Mol Cell Biol. 2000 Jun;20(11):4106-14
pubmed: 10805752
Glia. 2019 May;67(5):844-856
pubmed: 30588668
J Neuroinflammation. 2018 Nov 6;15(1):307
pubmed: 30400912
Science. 2021 Apr 23;372(6540):
pubmed: 33888612
Cell Tissue Res. 2010 Jan;339(1):31-46
pubmed: 19597846
Methods Mol Biol. 2019;2034:41-55
pubmed: 31392676

Auteurs

Anne-Laure Hemonnot-Girard (AL)

IGF, Univ. Montpellier, CNRS, INSERM, Montpellier, France.
LabEx Ion Channel Science and Therapeutics, Lyon, France.

Cédric Meersseman (C)

IGF, Univ. Montpellier, CNRS, INSERM, Montpellier, France.
LabEx Ion Channel Science and Therapeutics, Lyon, France.

Manuela Pastore (M)

Université de Montpellier, CNRS, INSERM, BioCampus UAR3426, Montpellier, France.

Valentin Garcia (V)

IGF, Univ. Montpellier, CNRS, INSERM, Montpellier, France.
LabEx Ion Channel Science and Therapeutics, Lyon, France.

Nathalie Linck (N)

IGF, Univ. Montpellier, CNRS, INSERM, Montpellier, France.
LabEx Ion Channel Science and Therapeutics, Lyon, France.

Catherine Rey (C)

ProfileXpert, SFR santé Lyon-Est, CNRS UMR-S3453, Inserm US7, Lyon, France.

Amine Chebbi (A)

ProfileXpert, SFR santé Lyon-Est, CNRS UMR-S3453, Inserm US7, Lyon, France.

Freddy Jeanneteau (F)

IGF, Univ. Montpellier, CNRS, INSERM, Montpellier, France.

Stephen D Ginsberg (SD)

Center for Dementia Research, Nathan Kline Institute, Orangeburg, New-York, USA.
Department of Psychiatry, Department of Neuroscience & Physiology, and the NYU Neuroscience Institute, New York University Grossman School of Medicine, New York, USA.

Joël Lachuer (J)

University Lyon1, CRCL-Centre de Recherche en Cancérologie de Lyon-Inserm U1052-CNRS U5286, Lyon, France.
ProfileXpert, SFR santé Lyon-Est, CNRS UMR-S3453, Inserm US7, Lyon, France.

Christelle Reynes (C)

Université de Montpellier, CNRS, INSERM, BioCampus UAR3426, Montpellier, France.

François Rassendren (F)

IGF, Univ. Montpellier, CNRS, INSERM, Montpellier, France.
LabEx Ion Channel Science and Therapeutics, Lyon, France.

Hélène Hirbec (H)

IGF, Univ. Montpellier, CNRS, INSERM, Montpellier, France. helene.hirbec@igf.cnrs.fr.
LabEx Ion Channel Science and Therapeutics, Lyon, France. helene.hirbec@igf.cnrs.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH